Only data that are available via publications-and, to a certain extent, via presentations at conferences-can contribute to progress in the life sciences. However, it has long been known that a strong publication bias exists, in particular against the publication of data that do not reproduce previously published material or that refute the investigators' initial hypothesis. The latter type of contradictory evidence is commonly known as 'negative data.' This slightly derogatory term reflects the bias against studies in which investigators were unable to reject their null hypothesis (H 0 ), a tool of frequentist statistics that states that there is no difference between experimental groups.
Researchers are well aware of this bias, as journals are usually not keen to publish the nonexistence of a phenomenon or treatment effect. They know that editors have little interest in publishing data that refute, or do not reproduce, previously published work-with the exception of spectacular cases that guarantee the attention of the scientific community, as well as garner extra citations (Ioannidis and Trikalinos, 2005) . The authors of negative results are required to provide evidence for failure to reject the null hypothesis under numerous conditions (e.g., dosages, assays, outcome parameters, additional species or cell types), whereas a positive result would be considered worthwhile under any of these conditions (Rockwell et al, 2006) . Indeed, there is a dilemma: one can never prove the absence of an effect, because, as Altman and Bland (1995) remind us, 'absence of evidence is not evidence of absence'.
It has been demonstrated that studies reporting positive, or significant, results are more likely to be published, and outcomes that are statistically significant have higher odds of being fully reported (Dwan et al, 2008) . Negative results are more likely than positive results to be published in journals with lower impact factors (Littner et al, 2005) . Many of you have experienced this phenomenon yourselves-often scientists mention in conversation that they 'were not able to reproduce' a particular finding, a statement that is very often countered by the question 'Why did you not publish this? It would have been important for me to know. ' Publication bias has been systematically investigated, particularly in clinical trials (e.g., Liebeskind et al, 2006) . Systematic reviews and meta-analyses have exposed the problem, as they are heavily confounded by this phenomenon (Sutton et al, 2000) . Given a sufficiently large number of original studies, meta-analysis can even quantify the bias attributable to unpublished data. Where this has been done-for example, with Egger plots and trimand-fill analysis -imputation of the probable results of the unpublished experiments not only reveals the amount of missing data but also estimates 'true' effect sizes resulting from the inclusion of the missing data. Quite commonly, a substantial proportion of the existing data appears to be missing. Inclusion of the modeled missing data into the meta-analysis sometimes results in a complete loss of the published effect of an intervention or the existence of a phenomenon. In many cases effect sizes shrink dramatically, hinting at the fact that very often the literature represents the 'positive' tip of an iceberg, whereas unpublished data loom below the surface. Such missing data would have the potential to have a significant impact on our pathophysiological understanding or treatment concepts.
Only recently have systematic reviews been introduced into experimental medicine. Indeed, the stroke and cerebrovascular fields have pioneered this movement. These systematic reviews have exposed various sources of bias and produced the first indications that publication bias is highly prevalent (Macleod et al, 2004) . Macleod and colleagues have now, for the first time, quantified publication bias in animal stroke studies and demonstrated that it leads to major overstatements of efficacy (Sena et al, 2010) .
The phenomenon of publication bias has long been known and long been bemoaned. Its substantial negative impact on science has been quantified. But how can we improve this lamentable situation, which may contribute greatly to our difficulties in translating bench findings to the bedside? The impetus must now come from the journals and publishers (De Maria, 2004; Diguet et al, 2004; Dirnagl, 2006; Knight, 2003) . To our knowledge, only one journal in the neurosciences, Neurobiology of Aging, has thus far formally addressed the problem of negative publication bias by introducing a special section (Coleman, 2004) . The Journal of Negative Results in Biomedicine (a BioMed Central publication) provides a forum for negative results and 'promotes a discussion of unexpected, controversial, provocative and/or negative results in the context of current tenets' (Pfeffer and Olsen, 2002) . However, the latter has developed into an eclectic repository in which relevant results may not receive the exposure they deserve.
As part of its drive to improve quality in experimental research (Dirnagl, 2006; MacLeod et al, 2009) , the Journal of Cerebral Blood Flow and Metabolism, together with the Nature Publishing Group, is tackling negative publication bias by introducing a Negative Results section. Each such study will be published as a one-page summary (maximum 500 words, two figures) in the print edition of the journal, and the accompanying full paper will appear online.
We invite authors to submit data that did not substantiate their alternative hypotheses (i.e., a difference between experimental groups) and/or did not reproduce published findings. A common criticism of the publication of negative results is that the experimentation involved may not have been as extensive as in research with positive results, which are often further complemented by additional, mechanistic experiments. A survey of the existing literature exposes this as wishful thinking, as most experimental studies are grossly underpowered. Importantly, the quality of the data submitted to our Negative Results section must meet the same rigorous standards that our journal applies to all other submissions. In fact, it may be said that the standards must even exceed those applied currently, as type II error (false negatives) considerations need to be included. Of note, in clinical studies, a priori sample-size calculations (at given levels for type I and II error, a and b) are mandatory. Experimental medicine has deplorably escaped this requirement, at least partially explaining why experimental results often have a very low positive predictive value.
The Negative Results section of the Journal of Cerebral Blood Flow and Metabolism will provide a platform and raise awareness of a problem with a proven negative impact on scientific progress as well as bench-to-bedside translation. Now researchers must step up to this platform. It is an experiment, but, if successful, it may serve as a role model for other journals and other research fields and thus help to reduce publication bias.
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